Mould Infections of Traumatic Wounds: A Brief Narrative Review

Provide enhanced digital features for this article This Figshare page contains a summary slide. If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact [email protected]. The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content. Other enhanced features include, but are not limited to: • Slide decks • Videos and animations • Audio abstracts • Audio slides</p

Efficacy and Safety of Meropenem-Vaborbactam versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients without Prior Antimicrobial Failure: A Post-hoc Analysis

Full copyright for enhanced digital features is owned by the authors.Provide enhanced digital features for this article If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact [email protected]. The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content. Other enhanced features include, but are not limited to: • Slide decks • Videos and animations • Audio abstracts • Audio slides</p

Should High Dose Daptomycin be an Alternative Treatment Regimen for Enterococcal Endocarditis?

Provide enhanced digital features for this article If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact [email protected]. The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content. Other enhanced features include, but are not limited to: • Slide decks • Videos and animations • Audio abstracts • Audio slides</p

Patient characteristics and incidence (episode/1000 person/day).

<p>Patient characteristics and incidence (episode/1000 person/day).</p

Number of death and 30 days/mortality for various <i>Candida spp</i>. and in the different hospital wards.

<p>Number of death and 30 days/mortality for various <i>Candida spp</i>. and in the different hospital wards.</p

Antifungal susceptibility test results for selected species of <i>Candida</i> isolated during the study period.

<p>SDD: susceptible dose dependence; na: breakpoint not available.</p><p>CLSI: Clinical and Laboratory Standards Institute; EUCAST: European Committee on Antimicrobial Susceptibility Testing.</p

Current and emerging drug treatment strategies to tackle invasive community-associated methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) infection: what are the challenges?

Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) infections represent a leading cause of purulent skin and soft tissue infections in some geographical regions. Traditionally, ‘old antibiotics’ such as trimethoprim-sulfamethoxazole, tetracyclines, clindamycin, chloramphenicol,vancomycin, and teicoplanin have been used to treat these infections, but these were often associated with low efficacy and excessive side effects and toxicity, especially nephrotoxicity. Along with the development of new compounds, the last decade has seen substantial improvements in the management of CA-MRSA infections. In this review, the authors discuss the current and emerging drug treatment strategies to tackle invasive CA-MRSA infections. Articles reported in this review were selected from through literature searches using the PubMed database. The availability of new drugs showing a potent in vitro activity against CA-MRSA represents a unique opportunity to face the threat of resistance while potentially reducing toxicity. All these compounds represent promising options to enhance our antibiotic armamentarium. However, data regarding the use of these new drugs in real-life studies are limited and their best placement in therapy and in terms of optimization of medical resources and balance of cost-effectiveness requires further investigation.</p

Additional file 1: of Procalcitonin levels in candidemia versus bacteremia: a systematic review

Search output from PubMed. Full search output from PubMed. (DOCX 299 kb

Additional file 2: of Procalcitonin levels in candidemia versus bacteremia: a systematic review

Search output from EMBASE. Full search output from EMBASE. (DOCX 88 kb

Distribution of the <i>Candida</i> species according to underlying pathology/medical care (n).

<p>Distribution of the <i>Candida</i> species according to underlying pathology/medical care (n).</p